Genetic Aspects of Drug Disposition and Therapeutics

POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN

1977 • 1,196 citations

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

1988 • 717 citations

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1979 • 647 citations

N-acetylation pharmacogenetics.

1985 • 637 citations

Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism

1989 • 605 citations

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1980 • 544 citations

Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs

1988 • 539 citations

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1985 • 386 citations

MEDICAL NEMESIS

1974 • 377 citations

Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

1984 • 368 citations

CARDIAC TOXICITY OF DAUNORUBICIN

1969 • 345 citations

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1989 • 292 citations

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

1987 • 281 citations

Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism

1984 • 271 citations

Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype

1989 • 257 citations

N-acetyltransferase

1989 • 237 citations

Ethnic Differences in Drug Metabolism

1982 • 229 citations

ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE

1985 • 228 citations

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

1989 • 221 citations

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

1983 • 215 citations

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

1982 • 213 citations

A simple test for acetylator phenotype using caffeine.

1984 • 211 citations

Genetically Determined Variability in Acetylation and Oxidation Therapeutic Implications

1985 • 197 citations

Recent Developments in Hepatic Drug Oxidation

1990 • 189 citations

Defective Oxidation of Drugs

1982 • 182 citations

Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

1989 • 178 citations

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

1985 • 173 citations

THE ÆTIOLOGY OF RETROGRADE AMNESIA

1971 • 173 citations

Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

1984 • 162 citations

Pharmacogenetics of Tolbutamide Metabolism in Humans

1978 • 160 citations

Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.

1987 • 152 citations

Pharmacogenetics of tolbutamide metabolism in humans

1979 • 136 citations

Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation

1983 • 123 citations

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin

1989 • 116 citations

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

1986 • 113 citations

Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children

1989 • 97 citations

Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.

1985 • 96 citations

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

1986 • 94 citations

Evidence for an enzymatic defect in the 4‐hydroxylation of debrisoquine by human liver.

1981 • 93 citations

Influence of genetic polymorphism on the metabolism and disposition of encainide in man.

1984 • 90 citations

Genetically determined polymorphisms in drug oxidation

1986 • 88 citations

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

1985 • 86 citations

Methyltransferase pharmacogenetics

1989 • 82 citations

Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.

1988 • 80 citations

Hypotensive response to debrisoquine and hydroxylation phenotype

1978 • 79 citations

Genetic variation in the human hepatic cytochrome P-450 system

1987 • 78 citations

Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man

1988 • 74 citations

S-METHYLATION IN MOTORNEURON DISEASE AND PARKINSON'S DISEASE

1989 • 67 citations

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers

1984 • 66 citations

Mephenytoin hydroxylation deficiency: Kinetics after repeated doses

1984 • 62 citations

Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency

1987 • 60 citations

Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

1989 • 57 citations

Evidence for polymorphic oxidation of sparteine in Japanese subjects.

1987 • 55 citations

Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2

1990 • 54 citations

Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo

1985 • 54 citations

Polymorphic drug metabolism.

1989 • 53 citations

Debrisoquine oxidation phenotype and susceptibility to lung cancer.

1990 • 51 citations

Stereo- and regioselectivity of hepatic oxidation in man ? Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation

1986 • 49 citations

Why hypertensive patients vary in their response to oral debrisoquine.

1977 • 46 citations

Pharmacokinetics of Nifedipine Slow Release Tablet in Mexican Subjects: Further Evidence for an Oxidation Polymorphism

1989 • 37 citations

The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

1989 • 37 citations

Genetic polymorphism of trimethylamine N-oxidation

1990 • 36 citations

Nifedipine: Variability in its kinetics and metabolism in man

1989 • 35 citations

Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

1990 • 35 citations

Relevance of genetic polymorphism in drug metabolism in the development of new drugs

1989 • 33 citations

Mephenytoin hydroxylation in the Cuna Amerindians of Panama.

1988 • 30 citations

Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.

1984 • 30 citations

Polymorphism of the 4-Hydroxylation of Debrisoquine in the San Bushmen of Southern Africa

1988 • 26 citations

Simplified Phenotyping with Dextromethorphan by Thin-Layer Chromatography

1988 • 26 citations

Effects of ketoconazole on the polymorphic 4‐hydroxylations of S‐ mephenytoin and debrisoquine.

1989 • 25 citations

Polymorphic metabolism of the ?-adrenoreceptor blocking drugs and its clinical relevance

1985 • 21 citations

A human cytochrome P-450 is recognized by anti-liver/kidney microsome antibodies in autoimmune chronic hepatitis

1989 • 20 citations

Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations

1986 • 19 citations

Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism.

1988 • 18 citations

Pharmacogenetics

1975 • 17 citations

From the Food and Drug Administration

1986 • 10 citations

Thin-Layer Chromatographic Screening Test for Polymorphic Sparteine Oxidation

1989 • 8 citations

New drug approval process: Clinical and regulatory management

1987 • 8 citations

A new polymorphism of hepatic drug oxidation in humans: family studies of antipyrine metabolites.

1984 • 6 citations

Commentary: drug metabolism and pharmacogenetics.

1983 • 5 citations